Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (VinoMetro)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03007992 |
|
Recruitment Status :
Completed
First Posted : January 2, 2017
Last Update Posted : August 12, 2019
|
Sponsor:
Johannes Gutenberg University Mainz
Collaborator:
Pierre Fabre Pharma GmbH
Information provided by (Responsible Party):
Marcus Schmidt, MD, Johannes Gutenberg University Mainz
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | March 2, 2019 |
| Actual Study Completion Date : | March 2, 2019 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):